<DOC>
	<DOCNO>NCT00950846</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness Umbilical Cord Blood Transplant ( UCBT ) treat patient 's disease , see treatment decrease incidence GVHD . This study patient born disease affect body 's metabolism immune system . The doctor plan treat patient illness stem cell transplant . While improved medical care allow many people disease live long , way truly cure disease mean stem cell transplant donor disease . A stem cell transplant replace sick cell new healthy donor cell . Stem cell grow different type blood cell people need , include red blood cell , white blood cell , platelet . In stem cell transplant , patient stem cell would kill chemotherapy drug replace stem cell donor . Stem cell collect bone marrow , peripheral blood umbilical cord . In study , umbilical cord source stem cell . Currently , large inventory umbilical cord blood unit available public bank transplantation lack bone marrow donor . UCB transplant offer several advantage adult bone marrow peripheral blood stem cell transplant , include : 1 . Rapid availability , 2 . Absence donor risk , 3 . Low risk transmissible infectious disease , 4 . Low risk acute GvHD ( compare recipient unrelated donor marrow peripheral blood cell ) . The two main cause death umbilical cord blood transplantation disorder kinds patient , graft failure infection . In study try address two problem use different drug prepare patient transplant . To help improve engraftment ( cell begin grow ) , include drug Fludarabine usually use Busulfan Cytoxan study patient receive transplant . We try decrease chance develop graft-versus-host disease ( GvHD ) use Cyclosporin A ( CSA ) Mycophenolate Mofetil ( MMF ) , instead Anti-Thymocyte Globulin ( ATG ) normally use .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplant Congenital Pediatric Disorders</brief_title>
	<detailed_description>Patients examine make sure meet requirement study . There test heart lung . X-rays take lung organ , depend disease . An MRI consultation different specialist also conduct . Patients also must negative pregnancy test enter study woman childbearing potential . The blood test virus look function liver kidney . The examination also include HIV testing . If patient HIV , able treat protocol . After determined patient eligible treatment study suitable UCB stem donor find , central line place . After placement central line , follow chemotherapy give admission hospital : - 9 day infusion 6 day infusion : Busulfan every 6 hour 16 total dos . - 5 day infusion 2 day infusion : Cytoxan give daily 4 day 2 hour . ( It give 1 4 hour need decide physician ) . Mesna give per standard . - 4 day infusion 1 day infusion : Fludarabine give daily 4 day 1 hour . Stem cell transplant ( infusion UCB stem cell ) - define Day 0 treatment . All `` numbered '' day relate infusion date . For example , Day 1 first day stem cell transplant . Standard Therapy : Phenytoin give accord standard TCH formulary . Cyclosporin A ( CSA ) give start 2 day prior stem cell infusion . It give daily 2 hour every 12 hour , taper GvHD present . Administration Mycophenolate Mofetil ( MMF ) start day stem cell infusion complete , continue daily 45 day unless patient develops GvHD . Intravenous Immunoglobulins ( IVIG ) give per CAGT SOP infection prophylaxis . Granulocyte Colony-Stimulating Factor ( GCSF ) give daily start Day +7 ANC great 2,500 three consecutive day . Study Evaluation : Patients various study evaluation , include blood sample , transplant . Follow-Up : After year 1 , patient ask return clinic year consultation . These consultation specialist similar one patient transplant .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients le 18 year age . Patients congenital acquire immunologic , hematological , metabolic pediatric disease ( include SCID ) stem cell transplantation beneficial . Related Unrelated Umbilical Cord Blood Unit 01 antigen mismatch , 56 HLA A B ( low intermediate resolution ) DRB1 ( high resolution ) . Total cryopreserved HSC graft cell dose must 5 x 10^7 great nucleate cell per kilogram recipient body weight . Lansky/Karnofsky score 60 great . Patient DLCO &gt; 50 % predict FEV1 &gt; 50 % , applicable . Written inform consent and/or sign assent line patient , parent guardian . EXCLUSION CRITERIA : Patients uncontrolled infection assess principal investigator . For bacterial infection , patient must receive definitive therapy sign progress infection 72 hour prior start conditioning . For fungal infection patient must receive definitive systemic antifungal therapy sign progress infection 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Severe renal disease ( creatinine &gt; 3X normal age ) . Severe hepatic disease ( direct bilirubin &gt; 3 mg/dL SGOT &gt; 500 ) . Patients symptomatic cardiac failure unrelieved medical therapy evidence significant cardiac dysfunction echocardiogram ( shorten fraction &lt; 20 % ) . HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Congenital Pediatric Disorders</keyword>
	<keyword>Umbilical Cord Blood Transplant</keyword>
	<keyword>Congenital Abnormalities</keyword>
	<keyword>Cord Blood Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
</DOC>